X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for T Cell Therapy and immunology discovery.
Lead Product(s): T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Merck to support up to six more research groups at the BioMed X Institute in Heidelberg within the next six years in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases).
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
